Johnson & Johnson

- Johnson & Johnson completed the Kenvue separation, generating significant cash and value for shareholders through Kenvue's debt offering and IPO. - The company reduced its outstanding share count by approximately 191 million shares (7%) and retained about 180 million shares of Kenvue stock, providing cash proceeds for future growth. - No specific mention of planned new fundraising through debt or equity in the near term. - J&J highlighted its strong credit profile and robust free cash flow to prioritize strategic business development, dividends, and share repurchases. - The net debt position is approximately $6 billion with $24 billion cash and marketable securities. - Future capital allocation will focus on disciplined investment without explicitly stating plans for new debt or equity issuance.

- Johnson & Johnson is progressively increasing manufacturing capacity for Carvykti, including: - Expanding the original launch site in New Jersey. - Commissioning a new manufacturing site in Belgium. - Utilizing excess capacity from Novartis. - Enhancing lentivirus component production at a factory in Switzerland. - Building a new factory in the Netherlands for lentivirus production, expected operational in 2024. - The company is implementing a restructuring program in MedTech, specifically in Orthopedics, to simplify and focus operations: - Exiting certain markets and product lines by the end of 2025. - Expect modest short-term revenue reduction (~$250 million over two years) but aiming for improved profitability and margin profile. - Johnson & Johnson plans to initiate multiple clinical development programs for targeted oral peptide J&J-2113, including phase 3 programs starting late 2023 and 2024. - Continued investments in innovation such as pulse field ablation technologies, surgical robotics, and cardiac ablation platforms.

- MedTech business growth expected to continue, with pro forma growth of 6.4% in recent quarters and procedural growth forecasted at 5% to 7% in 2024. - Launch of new products, such as first PFA catheter in Europe in 2024, expected to fuel MedTech growth. - Immunology business showing strong performance, especially Tremfya with 25.1% growth; further growth expected from upcoming indications like ulcerative colitis and Crohn's disease. - Pharmaceuticals group's $57 billion revenue target for 2025 remains achievable due to growth in key assets (Tremfya, Erleada, Uptravi, Darzalex) and pipeline advancements. - Multiple myeloma treatments Carvykti and Tecvayli showing strong demand and increasing adoption. - Orthopedics aiming to improve growth by focusing on high-growth segments and expanding portfolio. - China market considered a key growth driver despite certain pricing headwinds. - Overall expectations for healthy top-line growth into 2024; margin progression to follow depending on investments and pipeline success.

- Operational sales growth for full-year 2023 raised to 8.5%-9% (up $600 million at midpoint), adjusted operational sales growth at 7.2%-7.7% (constant currency). - Adjusted pre-tax operating margin expected to improve by approximately 50 basis points versus prior year in 2023. - Adjusted earnings per share guidance for 2023 increased by $0.10 at midpoint to range of $10.02 to $10.08, equating to 12.5% growth at midpoint. - Full impact of share reduction from Kenvue separation to be realized in 2024, benefiting EPS. - For 2024, margins expected similar to 2023 start; full margin guidance not provided yet, but some dis-synergies from business separation not expected to materially impact. - Continued strong earnings growth anticipated driven by key Innovative Medicines brands, new product launches, and procedural growth in MedTech. - Confident to meet $57 billion pharma revenue target by 2025, supported by pipeline and delayed biosimilar pressure on Stelara.

The provided pages do not contain specific information about the current or expected orderbook or pending orders for Johnson & Johnson. The discussion is mainly focused on: - Immunology portfolio growth (12.4%) despite Remicade biosimilars. - Progress and excitement about the Ottava robotic surgery platform with updates expected next month. - Growth prospects in MedTech and pharmaceuticals, including procedural growth and product launches. - Strong pipeline in Innovative Medicines with upcoming data presentations (e.g., MARIPOSA lung cancer trial). - Manufacturing capacity expansions for CAR T therapies like Carvykti to meet increasing demand. - Headwinds and opportunities in China’s market price policies. - Litigation updates and business development discipline. No explicit figures or details about orderbook or pending orders were disclosed in the transcript.